^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report

Excerpt:
We describe the case of a 50-year-old male presented intermittent macrohematuria and was diagnosed with bladder urothelial carcinoma...The tumor mutation burden (TMB) was 19.10 Mutants/Mb and the microsatellite state was stable (MSS). Furthermore, inactivating mutation in the RB1 gene was detected...The immunohistochemistry showed that the combined positive score (CPS) of the PD-L1 expression level was <1...The patient received a novel regimen of neoadjuvant chemotherapy plus pembrolizumab and subsequent chemoradiotherapy that successfully preserved his bladder with no immunotherapy-related adverse events.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.3389/fimmu.2021.684879